SynthesisBMC pharmacology & toxicology2026
The effect of CoQ10 supplementation on cardiovascular risk factors in patients with prediabetes and type 2 diabetes mellitus: a grade-assessed systematic review and dose-response meta-analysis.
Synthesis in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious research has shown that cardiovascular events are more prevalent among type 2 diabetes mellitus (T2DM) patients; therefore, it is vital to reduce cardiovascular risk factors in this population. Randomized controlled trials (RCTs) investigating the effects of coenzyme Q10 (CoQ10) supplementation on cardiovascular risk factors have reported inconsistent findings. As a result, we intended to assess the effects of CoQ10 supplementation on lipid and glucose profiles, blood pressure, oxidative stress, and inflammation in patients with prediabetes and T2DM.
methodsA systematic literature search was carried out using electronic databases, including PubMed, Web of Science, and Scopus, from inception to May 2025to identify eligible RCTs evaluating the effect of CoQ10 supplementation on cardiovascular risk factors. We used STATA software to combine the individual study results for all outcomes studied. Heterogeneity tests of the selected trials were performed using the I2 statistic. All analyses were performed using random-effects models to account for potential between-study heterogeneity, and pooled data were determined as the weighted mean difference with a 95% confidence interval.
resultsOf 4894 records, 20 eligible RCTs were included in the current meta-analysis. Our meta-analysis of the pooled findings showed that CoQ10 supplementation significantly reduced triglycerides (p=0.001), fasting blood sugar (p<0.001), hemoglobin A1c (p=0.004), Homeostatic Model Assessment for Insulin Resistance (p=0.028) and C-reactive protein (P<0.001), while increasing high-density lipoprotein (p= 0.003). However, CoQ10 supplementation did not significantly affect total cholesterol, low-density lipoprotein, systolic and diastolic blood pressure, and malondialdehyde.
conclusionsOverall, the results demonstrated that CoQ10 supplementation may improve several cardiovascular risk factors in patients with prediabetes and T2DM. However, further research with long-term interventions and diverse dosages is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.